NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $50.00. They now have a "buy" rating on the stock.
Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? [Yahoo! Finance]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December